Cargando…

Effect of upregulation of DD3 on early detection and prognosis in prostate cancer

BACKGROUND: Expression of prostate cancer antigen 3 (PCA3 OR DD3) in the blood has been reported to be significantly higher in prostate cancer (PCa) than in benign prostate hyperplasia (BPH). To confirm whether DD3 expression is significantly different between PCa and BPH tissues, DD3 expression was...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ke, Zhao, Huishan, Wang, Wenting, Zhu, Yingqian, Zhang, Xuebao, Ma, Jiajia, Tan, Haotian, Zhang, Yulian, Lin, Chunhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475679/
https://www.ncbi.nlm.nih.gov/pubmed/32944517
http://dx.doi.org/10.21037/tau-19-899
_version_ 1783579560310210560
author Wang, Ke
Zhao, Huishan
Wang, Wenting
Zhu, Yingqian
Zhang, Xuebao
Ma, Jiajia
Tan, Haotian
Zhang, Yulian
Lin, Chunhua
author_facet Wang, Ke
Zhao, Huishan
Wang, Wenting
Zhu, Yingqian
Zhang, Xuebao
Ma, Jiajia
Tan, Haotian
Zhang, Yulian
Lin, Chunhua
author_sort Wang, Ke
collection PubMed
description BACKGROUND: Expression of prostate cancer antigen 3 (PCA3 OR DD3) in the blood has been reported to be significantly higher in prostate cancer (PCa) than in benign prostate hyperplasia (BPH). To confirm whether DD3 expression is significantly different between PCa and BPH tissues, DD3 expression was tested in the blood both preoperatively and postoperatively and in the paired tissues of PCa patients. METHODS: Expression levels of DD3 mRNA in the blood of patients who did not undergo surgery (PCa, n=102; BPH, n=53), those underwent surgery (preoperative, n=35; postoperative, n=35), and in PCa tissue specimens (tumor, n=41; adjacent normal, n=21) were determined by real-time quantitative PCR. Sensitivity and specificity for DD3 in PCa patients were validated by receiver operating characteristic (ROC) curve analysis. RESULTS: Our data suggest that expression level of DD3 in blood samples was significantly higher in PCa patients than in BPH patients (P=0.005). Expression of DD3 mRNA was also significantly elevated in PCa tissues compared with adjacent normal tissues (P=0.013). The increase in DD3 expression in PCa patients was further validated using a dataset from The Cancer Genome Atlas (n=549). Postoperative DD3 expression decreased following surgical intervention (P<0.001). Moreover, low DD3 expression was associated with improved overall survival (OS). Using gene set enrichment analysis, DD3 expression was correlated with specific PCa target genes including carcinogenesis-related and cancer proliferation-related genes. CONCLUSIONS: This study demonstrated that expression of DD3 was upregulated in blood and PCa tumor tissues and was associated with prognosis. The oncogenic role of DD3 was further validated in the TCGA database, indicating that DD3 is a potential therapeutic target for PCa. Furthermore, this study suggests that DD3 expression could be considered as a prognostic biomarker for PCa.
format Online
Article
Text
id pubmed-7475679
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-74756792020-09-16 Effect of upregulation of DD3 on early detection and prognosis in prostate cancer Wang, Ke Zhao, Huishan Wang, Wenting Zhu, Yingqian Zhang, Xuebao Ma, Jiajia Tan, Haotian Zhang, Yulian Lin, Chunhua Transl Androl Urol Original Article BACKGROUND: Expression of prostate cancer antigen 3 (PCA3 OR DD3) in the blood has been reported to be significantly higher in prostate cancer (PCa) than in benign prostate hyperplasia (BPH). To confirm whether DD3 expression is significantly different between PCa and BPH tissues, DD3 expression was tested in the blood both preoperatively and postoperatively and in the paired tissues of PCa patients. METHODS: Expression levels of DD3 mRNA in the blood of patients who did not undergo surgery (PCa, n=102; BPH, n=53), those underwent surgery (preoperative, n=35; postoperative, n=35), and in PCa tissue specimens (tumor, n=41; adjacent normal, n=21) were determined by real-time quantitative PCR. Sensitivity and specificity for DD3 in PCa patients were validated by receiver operating characteristic (ROC) curve analysis. RESULTS: Our data suggest that expression level of DD3 in blood samples was significantly higher in PCa patients than in BPH patients (P=0.005). Expression of DD3 mRNA was also significantly elevated in PCa tissues compared with adjacent normal tissues (P=0.013). The increase in DD3 expression in PCa patients was further validated using a dataset from The Cancer Genome Atlas (n=549). Postoperative DD3 expression decreased following surgical intervention (P<0.001). Moreover, low DD3 expression was associated with improved overall survival (OS). Using gene set enrichment analysis, DD3 expression was correlated with specific PCa target genes including carcinogenesis-related and cancer proliferation-related genes. CONCLUSIONS: This study demonstrated that expression of DD3 was upregulated in blood and PCa tumor tissues and was associated with prognosis. The oncogenic role of DD3 was further validated in the TCGA database, indicating that DD3 is a potential therapeutic target for PCa. Furthermore, this study suggests that DD3 expression could be considered as a prognostic biomarker for PCa. AME Publishing Company 2020-08 /pmc/articles/PMC7475679/ /pubmed/32944517 http://dx.doi.org/10.21037/tau-19-899 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Ke
Zhao, Huishan
Wang, Wenting
Zhu, Yingqian
Zhang, Xuebao
Ma, Jiajia
Tan, Haotian
Zhang, Yulian
Lin, Chunhua
Effect of upregulation of DD3 on early detection and prognosis in prostate cancer
title Effect of upregulation of DD3 on early detection and prognosis in prostate cancer
title_full Effect of upregulation of DD3 on early detection and prognosis in prostate cancer
title_fullStr Effect of upregulation of DD3 on early detection and prognosis in prostate cancer
title_full_unstemmed Effect of upregulation of DD3 on early detection and prognosis in prostate cancer
title_short Effect of upregulation of DD3 on early detection and prognosis in prostate cancer
title_sort effect of upregulation of dd3 on early detection and prognosis in prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475679/
https://www.ncbi.nlm.nih.gov/pubmed/32944517
http://dx.doi.org/10.21037/tau-19-899
work_keys_str_mv AT wangke effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT zhaohuishan effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT wangwenting effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT zhuyingqian effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT zhangxuebao effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT majiajia effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT tanhaotian effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT zhangyulian effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer
AT linchunhua effectofupregulationofdd3onearlydetectionandprognosisinprostatecancer